| Similar Articles |
|---|
 |
Pharmaceutical Executive
April 1, 2012
William Looney |
IP: Time for a Reset? Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.   |
| Knowledge@Wharton |
Why High-Tech Firms Can't Afford to Ignore Patents When it comes to patents, high technology firms are, out of necessity, interdependent... |
InternetNews
May 20, 2005
Sean Michael Kerner |
A Primer on Software Patents A closer look at software patents and at their history and implications for IT. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Pharmaceutical Executive
December 1, 2010 |
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. |
Pharmaceutical Executive
June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Wall Street & Technology
September 19, 2006
Paul Allen |
Patent Processing For both the patent holders and potential transgressors, technology patents can be a high-stakes game in the financial world, in both monetary awards and ongoing business feasibility. |
Pharmaceutical Executive
March 1, 2013
Henninger & Feldstein |
Safeguarding the Value of Patent Assets As small biotech firms test the water in partnerships with Big Pharma, the best calling card is a well-framed strategy on intellectual property. |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
Pharmaceutical Executive
September 1, 2010
William Looney |
The Coming Second Act Reinvention takes more than a pithy redraft of the strategy plan or mission statement; money, a change in business culture, and the mindset of thousands of employees is required too. |
Pharmaceutical Executive
August 1, 2011
William Looney |
Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation. |
IEEE Spectrum
June 2007
Suhas Sreedhar |
Peer Review Starts for Software Patent Applications Hoping to curtail the orgy of tech-industry litigation, the U.S. Patent and Trademark Office recently launched an Internet-based peer-review program whereby anyone can help to evaluate a number of software patent applications voluntarily submitted for public evaluation. |
Pharmaceutical Executive
August 1, 2012
Carol Ann Williams |
Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine. |
Pharmaceutical Executive
January 1, 2012
William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
IndustryWeek
August 1, 2003
John Teresko |
Intellectual Property, It's Worth Keeping An Eye On Making sure intellectual property is protected can reap benefits and prevent hassles. |
Bank Technology News
July 2008
Glen Fest |
Intellectual Property on Trial The Financial Services Roundtable and several institutional members such as Bank of America are urging a federal court to overturn the patentability of certain business method processes. |
IndustryWeek
October 1, 2007
Jill Jusko |
Patent Protection Your valuable intellectual property requires keen oversight. To help keep it safe, consider these actions. |
Inc.
July 24, 2002
Jennifer A. Redmond |
Strategic Patenting What to consider when you're filing a patent and strategic decisions you'll need to make. |
CIO
September 28, 2012
Kim S. Nash |
Companies Race to the Patent Office to Protect Their IT Breakthroughs There's a patent gold rush under way as savvy companies seek to lock in the competitive advantage from their IT innovations. CIOs ought to seek patents for unique business methods and other inventions made possible by new technology. |
InternetNews
January 11, 2005
Jim Wagner |
IBM Pledges Patents to Open Source IBM said Tuesday it is pledging 500 software patents to developers of open source software so they can develop without fear. The patents are available to those who abide by the Open Source Initiative (OSI) and use one of 50 OSI-certified licenses. |
IEEE Spectrum
March 2009
Steven J. Frank |
The Death of Business-Method Patents From now on, you can get a U.S. patent only on a mousetrap -- not on the idea of catching mice |
Pharmaceutical Executive
May 1, 2005
Margaret Buck |
Legal: No Exception? An important legal loophole has made patented tools available for biotech research. Today, though, it appears to be closing. |
CIO
January 1, 2003
Christopher Koch |
Patently Stupid? It's not clear at the start of 2003 whether the software patent frenzy will cause innovation to flower or be trampled. |
Chemistry World
January 17, 2013
Simon Hadlington |
Nanotech patent jungle set to become denser in 2013 As we welcome in 2013, will nanotechnology continue to dominate many of the scientific headlines in the coming year, just as it has done over the past decade? |
InternetNews
January 28, 2008
Stuart J. Johnston |
Microsoft: King of The Patent Hill Microsoft emerges as top tech patent holder with more than 15,000 patents pending. |
Financial Advisor
October 2006
Michael Brier |
Patently Foolish? Allowing financial firms to patent tax strategies may mean you and your clients have to foot the bill. |
Pharmaceutical Executive
September 1, 2012
Roy F. Waldron |
Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? |
The Motley Fool
September 17, 2011 |
What's Fueling the Tech Patent Bull Market? As companies amass patents to sue each other, is it time for the patent system to be reformed? |
The Motley Fool
March 31, 2010
Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
Salon.com
April 24, 2000
Mark Compton |
Lean, green gene-counting machine Incyte CEO Roy Whitfield gives biotech investors and patent critics a few lessons on genomic research. |
InternetNews
March 28, 2011 |
What is the Value of Red Hat's Patents? Linux leader Red Hat has now been recognized for the strength of its patents, what is it doing with all that intellectual property? |
CFO
December 1, 2011
Marielle Segarra |
Putting a Price on Patents CFOs can play a critical role in bringing financial discipline to their companies' intellectual-property portfolios. |
Bank Systems & Technology
March 27, 2008
Maria Bruno-Britz |
Patent Issues a Growing Concern for Banks Unfortunately for the banking industry, legal wrangling around financial services patents is becoming all too common. |
Chemistry World
April 8, 2013
Sarah Houlton |
India rejects Novartis patent appeal India's Supreme Court has denied Novartis' appeal against the decision to refuse patent protection for its anticancer drug Glivec (imatinib mesylate). |
Entrepreneur
September 2003
David Newton |
Now Showing Win partners by letting them see what you're made of -- with a "portfolio" of your patented technology. |
HBS Working Knowledge
June 9, 2008
Sean Silverthorne |
Monetizing IP: The Executive's Challenge In this Q&A, Harvard Business School professor Josh Lerner discusses current trends in Intellectual property, including the rise of patent pools. |
Chemistry World
October 2006 |
Head to Head For: Patents protect inventions by giving the owner of the patent the right to stop anyone from making or using the invention without the owner's permission... Against: Patents are a menace... |
Pharmaceutical Executive
February 4, 2011
William Looney |
The Night Stalkers: Keeping CEOs Awake in 2011 The consensus is that 2011 will be a bad year for Big Pharma. Let's inventory a few of the 'night stalkers -- issues that are likely to keep members of the C-suite awake beyond a sensible 'lights out' time. |
IEEE Spectrum
December 2005
Steven J. Frank |
Patent Reform Cacophy The Patent Reform Act may, in the end, merely contribute another layer of cost, delay, and uncertainty. |
InternetNews
November 24, 2004
Jim Wagner |
Nick Godici, Commissioner for Patents, USPTO The U.S. Patent & Trademark Office has been taking a lot of heat in recent years over software patents. Sitting at the center of the firestorm, and the patent process, is Nick Godici, the agency's Commissioner for Patents. |
Information Today
October 16, 2006
K. Matthew Dames |
The Patent System on Tilt: IBM Seeks to Change the Game IBM wants to change the way the patent system works, holding itself out as an exemplar of openness. |
Chemistry World
March 9, 2011
Andrew Turley |
Court halts EU patent progress The intellectual property community will have to wait a little longer for its one-size-fits-all European patent, following a key ruling from the Court of Justice of the European Union |
The Motley Fool
June 1, 2007
Brian Lawler |
The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world. |
Pharmaceutical Executive
December 1, 2012
William Looney |
The Puzzle Master: Dr. Guido Rasi Europe's chief regulator charts a strategy from many moving parts. |
Bank Technology News
January 2004
Karen Krebsbach |
Bight Ideas Financial services firms are deluging the U.S. Patent and Trademark Office with applications, which soared 15-fold between 1995 and 2002. Patent attorney Dale Lazar urges banks to get in line: converting valuable ideas into assets can pay off big time. |
Bio-IT World
November 12, 2002
Sue Mayer |
Are Gene Patents in the Public Interest? Two recent studies from Britain argue against the unbridled patenting of genes and raise tough ethical questions. |
InternetNews
July 31, 2007
Larry Barrett |
RealNetworks Case Highlights Sea-Change In Patent Law Supreme Court ruling puts patent trolls on notice. |
Information Today
July 21, 2011
Barbara Quint |
Thomson IP Management Services Upgrades IP Manager There are other IP management software providers, but Thomson has a unique advantage in the patent area when it comes to data validation. |
Chemistry World
December 8, 2011
Sarah Houlton |
Academia Grows Its Role in Drug Discovery The number of pharma patents being filed by universities around the world is soaring compared with those coming from industry. |
